CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 284 enrolled
Drug / intervention
Dexamethasone +1 moredrug
Likely dose
Dexamethasone 700 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02121262
NCT02121262Phase 3Completed

Dexamethasone Posterior Segment Drug Delivery System Versus Laser Photocoagulation in Patients With Diabetic Macular Edema

Allergan·interventional·Posted Apr 23, 2014·Updated Nov 17, 2020

In Brief

A Phase 3 clinical trial evaluating Dexamethasone and Laser Photocoagulation for Macular Edema. Completed, enrolled 284 participants across 18 sites in 2 countries.

Detailed Summary

This study will evaluate the safety and efficacy of 700 μg dexamethasone versus laser photocoagulation in participants with diabetic macular edema (DME).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Edema
CountriesChina, Philippines

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 23, 2014
Enrollment StartJan 8, 2016
Primary CompletionNov 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 12.2 years ago

Interventions

Dexamethasonedrug

Dexamethasone 700 μg intravitreal injection in the study eye on Day 1, Months 5, and 10.

Laser Photocoagulationprocedure

Laser photocoagulation on Day 1, and on Months 3, 6, and 9, if retreatment indicated.